A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
Saved in:
| Title: | A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC. |
|---|---|
| Authors: | Wu H; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Liu C; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Yuan Q; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Qiao Y; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Ding Y; Department of Pathophysiology, Shaoxing People Hospital, Shaoxing, China., Duan L; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Li W; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Zhang M; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Zhang X; The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, China., Jiang Y; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Lu J; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Dong Z; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China., Wang T; Telethon Kids Institute, University of Western Australia, Perth, Australia.; The College of Nursing and Health, Zhengzhou University, Zhengzhou, China., Liu K; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, China., Zhao J; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Henan Provincial Cooperative Innovation Center for Cancer Chemo- prevention, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, China. |
| Source: | Oncoimmunology [Oncoimmunology] 2023 Nov 27; Vol. 12 (1), pp. 2282250. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2162-402X |
|---|---|
| DOI: | 10.1080/2162402X.2023.2282250 |
